Andrew J. Muir, MD, MHS
Clinical Director, Hepatology
Department / Division
Medicine /
Medicine - Gastroenterology
Address
DUMC 3913
Durham, NC 27710
Appointment Telephone
919-684-6437
Office Telephone
919-684-2052
Fax Telephone
919-684-8264
- MD, Duke University School of Medicine, 1993
- Internal Medicine, Duke University Medical Center, 1993-1996 (Chief Resident, 1997-1998)
- Gastroenterology, Duke University Medical Center, 1996-1997, 1998-2000
Clinical Interests
General hepatology, transplant hepatology, hepatitis C, hepatocellular carcinoma
Research Interests
· Hepatitis C
· Liver Transplantation
· Hepatocellular carcinoma
· Clinical Trials
· Racial disparities in liver disease
· Outcomes Research
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Abbott Laboratories
- Anadys Pharmaceuticals, Inc.
- Bristol-Myers Squibb
- Cook Medical
- Genentech, Inc (Roche Holding)
- Gilead Sciences, Inc.
- GlobeImmune, Inc.
- Idera Pharmaceuticals
- Medtronic Inc.
- Merck & Co. USA (not assoc'd with Merck KGaA)
- Pfizer Inc.
- Pharmasset, Inc. (Gilead)
- Salix Pharmaceuticals, Ltd.
- Santaris Pharma
- Scynexis
- Three Rivers Pharmaceuticals
- Vertex Pharmaceuticals Inc.
Representative Publications
Muir AJ, Hu KQ, Gordon SC, Koury K, Boparai N, Noviello S, Albrecht JK, Sulkowski MS, McCone J. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat. 2011 Apr;18(4):e134-43.
(2011)
Abstract
Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011 Nov;54(5):1538-46.
(2011)
Abstract
Muir AJ. The protease inhibitor era: an opportunity to improve the quality of care. Dig Dis Sci. 2011 May;56(5):1252-4.
(2011)
Abstract
Jou JH, Chen PH, Jazwinski A, Bouneva I, Smith AD, Muir AJ. Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. Dig Dis Sci. 2010 Dec;55(12):3591-6.
(2010)
Abstract
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, . Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010 Apr 8;362(14):1292-303.
(2010)
Abstract
Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep;52(3):822-32.
(2010)
Abstract
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17;461(7262):399-401.
(2009)
Abstract
McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, . Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009 Apr 30;360(18):1827-38.
(2009)
Abstract
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, . Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6;361(6):580-93.
(2009)
Abstract
Brady CW, Smith AD, Stechuchak KM, Coffman CJ, Tuttle-Newhall JE, Provenzale D, Muir AJ. Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. Liver Transpl. 2008 Feb;14(2):228-34.
(2008)
Abstract
Jou JH, Muir AJ. In the clinic. Hepatitis C. Ann Intern Med. 2008 Jun 3;148(11):ITC6-1-ITC6-16.
(2008)
Abstract
Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008 Aug;49(2):163-9.
(2008)
Abstract
Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006 Apr 29;332(7548):1013-7.
(2006)
Abstract
Ramamurthy M, Muir AJ. Treatment of hepatitis C in special populations. Clin Liver Dis. 2006 Nov;10(4):851-65.
(2006)
Abstract
Condron SL, Heneghan MA, Patel K, Dev A, McHutchison JG, Muir AJ. Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation. 2005 Jul 15;80(1):145-8.
(2005)
Abstract
Muir AJ, Bornstein JD, Killenberg PG, . Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004 May 27;350(22):2265-71.
(2004)
Abstract
